Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced it is buying Chimerix (Nasdaq: CMRX) for $8.55 per share in cash, representing a total consideration of approximately $935 million. The price is at a 75% premium and the deal is expected to close in the second quarter of 2025.
Jazz said that the acquisition will create…
Please login to read all 626 words.
